مصطلحات الفهرس: breast cancer, cancer incidence, cancer mortality, cancer patient, cancer risk, cancer survival, cohort analysis, controlled study, disease burden, female, health care cost, health care utilization, hematologic malignancy, human, lung cancer, major clinical study, malignant neoplasm/dt [Drug Therapy], melanoma, proportional hazards model, prospective study, risk factor, standardized incidence ratio, systemic sclerosis/di [Diagnosis], systemic sclerosis/dm [Disease Management], systemic sclerosis/dt [Drug Therapy], treatment outcome, abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], DNA directed RNA polymerase III/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], rituximab/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], male, adult, article, Australian, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28980Test
Arthritis Care and Research
Click here for full text options
LibKey Link

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085Test
Arthritis Care and Research
Click here for full text options
LibKey Link

مصطلحات الفهرس: breast cancer, cancer incidence, cancer mortality, cancer patient, cancer risk, cancer survival, cohort analysis, controlled study, disease burden, female, health care cost, health care utilization, hematologic malignancy, human, lung cancer, major clinical study, malignant neoplasm/dt [Drug Therapy], melanoma, proportional hazards model, prospective study, risk factor, standardized incidence ratio, systemic sclerosis/di [Diagnosis], systemic sclerosis/dm [Disease Management], systemic sclerosis/dt [Drug Therapy], treatment outcome, abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], DNA directed RNA polymerase III/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], rituximab/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], male, adult, article, Australian, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28980Test
Arthritis Care and Research
LibKey Link

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085Test
Arthritis Care and Research
LibKey Link

مصطلحات الفهرس: azathioprine/dt [Drug Therapy], biological product/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], iloprost/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], myeloblastin/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], neutrophil cytoplasmic antibody/ec [Endogenous Compound], penicillamine/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], scl 70 antibody/ec [Endogenous Compound], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], unclassified drug, vasodilator agent/dt [Drug Therapy], proteinase 3 antibody/ec [Endogenous Compound], myeloperoxidase antibody/ec [Endogenous Compound], adult, age, ANCA associated vasculitis/co [Complication], article, clinical feature, cohort analysis, comorbidity, disease association, female, human, interstitial lung disease/co [Complication], lung embolism/co [Complication], major clinical study, male, middle aged, mortality rate, prevalence, prognosis, prognostic assessment, sex, survival analysis, synovitis/co [Complication], systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], autoantibody/ec [Endogenous Compound], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35301Test
Arthritis Research and Therapy
Click here for full text options
LibKey Link

مصطلحات الفهرس: azathioprine/dt [Drug Therapy], biological product/dt [Drug Therapy], calcium channel blocking agent/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], iloprost/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], myeloblastin/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], neutrophil cytoplasmic antibody/ec [Endogenous Compound], penicillamine/dt [Drug Therapy], phospholipid antibody/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], scl 70 antibody/ec [Endogenous Compound], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], unclassified drug, vasodilator agent/dt [Drug Therapy], proteinase 3 antibody/ec [Endogenous Compound], myeloperoxidase antibody/ec [Endogenous Compound], adult, age, ANCA associated vasculitis/co [Complication], article, clinical feature, cohort analysis, comorbidity, disease association, female, human, interstitial lung disease/co [Complication], lung embolism/co [Complication], major clinical study, male, middle aged, mortality rate, prevalence, prognosis, prognostic assessment, sex, survival analysis, synovitis/co [Complication], systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], autoantibody/ec [Endogenous Compound], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35301Test
Arthritis Research and Therapy
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: abatacept/pe [Pharmacoeconomics], ambrisentan/dt [Drug Therapy], ambrisentan/pe [Pharmacoeconomics], angiotensin receptor antagonist/dt [Drug Therapy], angiotensin receptor antagonist/pe [Pharmacoeconomics], antiarrhythmic agent/dt [Drug Therapy], antiarrhythmic agent/pe [Pharmacoeconomics], antibiotic agent/dt [Drug Therapy], antibiotic agent/pe [Pharmacoeconomics], antilipemic agent/dt [Drug Therapy], antilipemic agent/pe [Pharmacoeconomics], azathioprine/dt [Drug Therapy], azathioprine/pe [Pharmacoeconomics], beta adrenergic receptor blocking agent/dt [Drug Therapy], beta adrenergic receptor blocking agent/pe [Pharmacoeconomics], bosentan/dt [Drug Therapy], bosentan/pe [Pharmacoeconomics], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/pe [Pharmacoeconomics], cyclosporin/dt [Drug Therapy], cyclosporin/pe [Pharmacoeconomics], dipeptidyl carboxypeptidase inhibitor/pe [Pharmacoeconomics], diuretic agent/dt [Drug Therapy], diuretic agent/pe [Pharmacoeconomics], histamine H2 receptor antagonist/dt [Drug Therapy], histamine H2 receptor antagonist/pe [Pharmacoeconomics], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pe [Pharmacoeconomics], iloprost/dt [Drug Therapy], iloprost/pe [Pharmacoeconomics], leflunomide/dt [Drug Therapy], leflunomide/pe [Pharmacoeconomics], macitentan/dt [Drug Therapy], macitentan/pe [Pharmacoeconomics], methotrexate/dt [Drug Therapy], methotrexate/pe [Pharmacoeconomics], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/pe [Pharmacoeconomics], penicillamine/dt [Drug Therapy], penicillamine/pe [Pharmacoeconomics], prednisolone/dt [Drug Therapy], prednisolone/pe [Pharmacoeconomics], prostacyclin/pe [Pharmacoeconomics], proton pump inhibitor/dt [Drug Therapy], proton pump inhibitor/pe [Pharmacoeconomics], rituximab/dt [Drug Therapy], rituximab/pe [Pharmacoeconomics], sildenafil/dt [Drug Therapy], sildenafil/pe [Pharmacoeconomics], tadalafil/dt [Drug Therapy], tadalafil/pe [Pharmacoeconomics], tocilizumab/dt [Drug Therapy], tocilizumab/pe [Pharmacoeconomics], tumor necrosis factor inhibitor/dt [Drug Therapy], tumor necrosis factor inhibitor/pe [Pharmacoeconomics], unindexed drug, prostacyclin/dt [Drug Therapy], ambulatory care, article, Australia, cardiovascular disease/dt [Drug Therapy], data analysis, drug cost, economic aspect, emergency care, gastrointestinal disease/dt [Drug Therapy], health care cost, health care utilization, hospital patient, hospitalization cost, human, prevalence, priority journal, pulmonary hypertension/dt [Drug Therapy], quantitative analysis, systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38696Test
Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: abatacept/pe [Pharmacoeconomics], ambrisentan/dt [Drug Therapy], ambrisentan/pe [Pharmacoeconomics], angiotensin receptor antagonist/dt [Drug Therapy], angiotensin receptor antagonist/pe [Pharmacoeconomics], antiarrhythmic agent/dt [Drug Therapy], antiarrhythmic agent/pe [Pharmacoeconomics], antibiotic agent/dt [Drug Therapy], antibiotic agent/pe [Pharmacoeconomics], antilipemic agent/dt [Drug Therapy], antilipemic agent/pe [Pharmacoeconomics], azathioprine/dt [Drug Therapy], azathioprine/pe [Pharmacoeconomics], beta adrenergic receptor blocking agent/dt [Drug Therapy], beta adrenergic receptor blocking agent/pe [Pharmacoeconomics], bosentan/dt [Drug Therapy], bosentan/pe [Pharmacoeconomics], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/pe [Pharmacoeconomics], cyclosporin/dt [Drug Therapy], cyclosporin/pe [Pharmacoeconomics], dipeptidyl carboxypeptidase inhibitor/pe [Pharmacoeconomics], diuretic agent/dt [Drug Therapy], diuretic agent/pe [Pharmacoeconomics], histamine H2 receptor antagonist/dt [Drug Therapy], histamine H2 receptor antagonist/pe [Pharmacoeconomics], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pe [Pharmacoeconomics], iloprost/dt [Drug Therapy], iloprost/pe [Pharmacoeconomics], leflunomide/dt [Drug Therapy], leflunomide/pe [Pharmacoeconomics], macitentan/dt [Drug Therapy], macitentan/pe [Pharmacoeconomics], methotrexate/dt [Drug Therapy], methotrexate/pe [Pharmacoeconomics], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/pe [Pharmacoeconomics], penicillamine/dt [Drug Therapy], penicillamine/pe [Pharmacoeconomics], prednisolone/dt [Drug Therapy], prednisolone/pe [Pharmacoeconomics], prostacyclin/pe [Pharmacoeconomics], proton pump inhibitor/dt [Drug Therapy], proton pump inhibitor/pe [Pharmacoeconomics], rituximab/dt [Drug Therapy], rituximab/pe [Pharmacoeconomics], sildenafil/dt [Drug Therapy], sildenafil/pe [Pharmacoeconomics], tadalafil/dt [Drug Therapy], tadalafil/pe [Pharmacoeconomics], tocilizumab/dt [Drug Therapy], tocilizumab/pe [Pharmacoeconomics], tumor necrosis factor inhibitor/dt [Drug Therapy], tumor necrosis factor inhibitor/pe [Pharmacoeconomics], unindexed drug, prostacyclin/dt [Drug Therapy], ambulatory care, article, Australia, cardiovascular disease/dt [Drug Therapy], data analysis, drug cost, economic aspect, emergency care, gastrointestinal disease/dt [Drug Therapy], health care cost, health care utilization, hospital patient, hospitalization cost, human, prevalence, priority journal, pulmonary hypertension/dt [Drug Therapy], quantitative analysis, systemic sclerosis/dt [Drug Therapy], abatacept/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38696Test
Medicine
Click here for full text options
LibKey Link